Skip to main content

Respondents Average 3.2 Small Molecule Sterile Injectables in Their Development Pipelines

By August 8, 2017December 20th, 2021No Comments

Informing the pharmaceutical drug development, manufacturing and commercialization industry.

Cary, NC – August 8, 2017 –  Industry Standard Research’s (ISR’s) Small Molecule Sterile Injectable Drug Product Manufacturing Market Overview and Outlook report looks specifically at the portfolios and pipelines of small molecule sterile injectable outsourcers to gauge future demand among outsourcers, to understand how contract manufacturers are selected and to offer insight into which kind of CMO – niche, full-service, or one-stop-shop – will best suit a drug innovator’s particular needs.

“Once the decision has been made to outsource, there are a multitude of factors that impact which CMO will be the best match for the project,” explained Kate Hammeke, Vice President of Market Research at ISR. “This report examines sterile injectable outsourcing decisions from several different angles to help drug innovators make informed decisions based on the successes of their outsourcing peers.”

Some of the outsourcing and contract manufacturer decision-making factors examined in the report are in-house levels of expertise and available capacity, the drug product’s therapeutic category, and delivery mechanism, and whether the product is in development or commercially available. “In this study, all research participants currently have products in development, but roughly one-third do not yet have a sterile injectable product on the market,” said Kate. “The addition of this group of drug innovators, who will be new to having a marketed sterile injectable product, will contribute to the increased demand for commercial capacity. This report is going to help CMOs better understand the future market and how to allocate resources to prepare for changes ahead.”

Key statistics from the report include: sterile injectable product volume, the proportion outsourced and the number of CMOs required for the work, in-house and outsourced manufacturing by region, CMO commercial engagement timelines, the likelihood of outsourcing a product by therapeutic category and delivery device, use of preferred providers and difficulty levels of using non-preferred CMOs, CMO familiarity, use, and preference (including verbatim preference responses from recent outsourcers for 21 different contract manufacturers), CMO selection and satisfaction drivers, and life cycle extension strategies for small molecule sterile injectable products.

CMOs included in the report are: Alcami, AbbVie Contract Manufacturing, Aenova, AMRI, Boehringer Ingelheim, Catalent, Cenexi, Coldstream Laboratories, Cook Pharmica, Delpharm, DPT, Dr. Reddy’s CPS, Fareva, Fresenius Kabi, Grand River Aseptic, GSK Contract Manufacturing, Hisun USA, Jubilant HollisterStier, Kemwell, Legacy Pharmaceuticals, Oakwood Laboratories, Patheon, Pfizer CentreOne, Pii, Pyramid Labs, Recipharm, Reig Jofre, ROVI CM, Sanofi CEPiA, Siegfried, Synerlab, Uman Pharmaceuticals, Vetter, and Wockhardt.

For more information on ISR’s “Small Molecule Sterile Injectable Drug Product Manufacturing Market Overview and Outlook” report, please visit ISR’s report page.

About Industry Standard Research

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s website at, email or follow ISR on Twitter @ISRreports.